Certified by Founder
Lodge
MSInsight
start up
France
- Paris
- 11/03/2025
- Seed
- $1,735,762
MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status.
MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker.
We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.
- Industry Medical Equipment Manufacturing
- Website https://www.msinsight.tech/
- LinkedIn https://www.linkedin.com/company/msinsight/
Iridius | $8,600,000 | (Apr 28, 2026)
Audion | $15,000,000 | (Apr 28, 2026)
Decade Energy | $25,763,540 | (Apr 28, 2026)
TriFetch | $1,900,000 | (Apr 28, 2026)
Fathom Therapeutics | $47,000,000 | (Apr 28, 2026)
SquareMind | $18,000,000 | (Apr 28, 2026)
Linexa | $2,342,840 | (Apr 28, 2026)
HrFlow.ai | $7,000,000 | (Apr 28, 2026)
Cnuic Technologies | $3,000,000 | (Apr 28, 2026)
Zócalo Health | $15,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)